Cargando…

Precision medicine in neurodegeneration: the IHI-PROMINENT project

Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Recent advances in diagnostics and approval for new pharmaceutical treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Tate, Ashley, Suárez-Calvet, Marc, Ekelund, Mats, Eriksson, Sven, Eriksdotter, Maria, Van Der Flier, Wiesje M., Georges, Jean, Kivipelto, Miia, Kramberger, Milica G., Lindgren, Peter, López, Juan Domingo Gispert, Lötjönen, Jyrki, Persson, Sofie, Pla, Sandra, Solomon, Alina, Thurfjell, Lennart, Wimo, Anders, Winblad, Bengt, Jönsson, Linus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433183/
https://www.ncbi.nlm.nih.gov/pubmed/37602259
http://dx.doi.org/10.3389/fneur.2023.1175922
_version_ 1785091593015918592
author Tate, Ashley
Suárez-Calvet, Marc
Ekelund, Mats
Eriksson, Sven
Eriksdotter, Maria
Van Der Flier, Wiesje M.
Georges, Jean
Kivipelto, Miia
Kramberger, Milica G.
Lindgren, Peter
López, Juan Domingo Gispert
Lötjönen, Jyrki
Persson, Sofie
Pla, Sandra
Solomon, Alina
Thurfjell, Lennart
Wimo, Anders
Winblad, Bengt
Jönsson, Linus
author_facet Tate, Ashley
Suárez-Calvet, Marc
Ekelund, Mats
Eriksson, Sven
Eriksdotter, Maria
Van Der Flier, Wiesje M.
Georges, Jean
Kivipelto, Miia
Kramberger, Milica G.
Lindgren, Peter
López, Juan Domingo Gispert
Lötjönen, Jyrki
Persson, Sofie
Pla, Sandra
Solomon, Alina
Thurfjell, Lennart
Wimo, Anders
Winblad, Bengt
Jönsson, Linus
author_sort Tate, Ashley
collection PubMed
description Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Recent advances in diagnostics and approval for new pharmaceutical treatments for Alzheimer’s disease (AD), the most common etiology of dementia, heralds the beginning of precision medicine in this field. However, their implementation will challenge an already over-burdened healthcare systems. There is a need for innovative digital solutions that can drive the related clinical pathways and optimize and personalize care delivery. Public-private partnerships are ideal vehicles to tackle these challenges. Here we describe the Innovative Health Initiative (IHI) public-private partnership project PROMINENT that has been initiated by connecting leading dementia researchers, medical professionals, dementia patients and their care partners with the latest innovative health technologies using a precision medicine based digital platform. The project builds upon the knowledge and already implemented digital tools from several collaborative initiatives that address new models for early detection, diagnosis, and monitoring of AD and other neurodegenerative disorders. The project aims to provide support to improvement efforts to each aspect of the care pathway including diagnosis, prognosis, treatment, and data collection for real world evidence and cost effectiveness studies. Ultimately the PROMINENT project is expected to lead to cost-effective care and improved health outcomes.
format Online
Article
Text
id pubmed-10433183
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104331832023-08-18 Precision medicine in neurodegeneration: the IHI-PROMINENT project Tate, Ashley Suárez-Calvet, Marc Ekelund, Mats Eriksson, Sven Eriksdotter, Maria Van Der Flier, Wiesje M. Georges, Jean Kivipelto, Miia Kramberger, Milica G. Lindgren, Peter López, Juan Domingo Gispert Lötjönen, Jyrki Persson, Sofie Pla, Sandra Solomon, Alina Thurfjell, Lennart Wimo, Anders Winblad, Bengt Jönsson, Linus Front Neurol Neurology Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Recent advances in diagnostics and approval for new pharmaceutical treatments for Alzheimer’s disease (AD), the most common etiology of dementia, heralds the beginning of precision medicine in this field. However, their implementation will challenge an already over-burdened healthcare systems. There is a need for innovative digital solutions that can drive the related clinical pathways and optimize and personalize care delivery. Public-private partnerships are ideal vehicles to tackle these challenges. Here we describe the Innovative Health Initiative (IHI) public-private partnership project PROMINENT that has been initiated by connecting leading dementia researchers, medical professionals, dementia patients and their care partners with the latest innovative health technologies using a precision medicine based digital platform. The project builds upon the knowledge and already implemented digital tools from several collaborative initiatives that address new models for early detection, diagnosis, and monitoring of AD and other neurodegenerative disorders. The project aims to provide support to improvement efforts to each aspect of the care pathway including diagnosis, prognosis, treatment, and data collection for real world evidence and cost effectiveness studies. Ultimately the PROMINENT project is expected to lead to cost-effective care and improved health outcomes. Frontiers Media S.A. 2023-08-02 /pmc/articles/PMC10433183/ /pubmed/37602259 http://dx.doi.org/10.3389/fneur.2023.1175922 Text en Copyright © 2023 Tate, Suárez-Calvet, Ekelund, Eriksson, Eriksdotter, Van Der Flier, Georges, Kivipelto, Kramberger, Lindgren, López, Lötjönen, Persson, Pla, Solomon, Thurfjell, Wimo, Winblad and Jönsson. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Tate, Ashley
Suárez-Calvet, Marc
Ekelund, Mats
Eriksson, Sven
Eriksdotter, Maria
Van Der Flier, Wiesje M.
Georges, Jean
Kivipelto, Miia
Kramberger, Milica G.
Lindgren, Peter
López, Juan Domingo Gispert
Lötjönen, Jyrki
Persson, Sofie
Pla, Sandra
Solomon, Alina
Thurfjell, Lennart
Wimo, Anders
Winblad, Bengt
Jönsson, Linus
Precision medicine in neurodegeneration: the IHI-PROMINENT project
title Precision medicine in neurodegeneration: the IHI-PROMINENT project
title_full Precision medicine in neurodegeneration: the IHI-PROMINENT project
title_fullStr Precision medicine in neurodegeneration: the IHI-PROMINENT project
title_full_unstemmed Precision medicine in neurodegeneration: the IHI-PROMINENT project
title_short Precision medicine in neurodegeneration: the IHI-PROMINENT project
title_sort precision medicine in neurodegeneration: the ihi-prominent project
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433183/
https://www.ncbi.nlm.nih.gov/pubmed/37602259
http://dx.doi.org/10.3389/fneur.2023.1175922
work_keys_str_mv AT tateashley precisionmedicineinneurodegenerationtheihiprominentproject
AT suarezcalvetmarc precisionmedicineinneurodegenerationtheihiprominentproject
AT ekelundmats precisionmedicineinneurodegenerationtheihiprominentproject
AT erikssonsven precisionmedicineinneurodegenerationtheihiprominentproject
AT eriksdottermaria precisionmedicineinneurodegenerationtheihiprominentproject
AT vanderflierwiesjem precisionmedicineinneurodegenerationtheihiprominentproject
AT georgesjean precisionmedicineinneurodegenerationtheihiprominentproject
AT kivipeltomiia precisionmedicineinneurodegenerationtheihiprominentproject
AT krambergermilicag precisionmedicineinneurodegenerationtheihiprominentproject
AT lindgrenpeter precisionmedicineinneurodegenerationtheihiprominentproject
AT lopezjuandomingogispert precisionmedicineinneurodegenerationtheihiprominentproject
AT lotjonenjyrki precisionmedicineinneurodegenerationtheihiprominentproject
AT perssonsofie precisionmedicineinneurodegenerationtheihiprominentproject
AT plasandra precisionmedicineinneurodegenerationtheihiprominentproject
AT solomonalina precisionmedicineinneurodegenerationtheihiprominentproject
AT thurfjelllennart precisionmedicineinneurodegenerationtheihiprominentproject
AT wimoanders precisionmedicineinneurodegenerationtheihiprominentproject
AT winbladbengt precisionmedicineinneurodegenerationtheihiprominentproject
AT jonssonlinus precisionmedicineinneurodegenerationtheihiprominentproject
AT precisionmedicineinneurodegenerationtheihiprominentproject